Home ProductsPharmaceutical Intermediates

Prilocaine Local Anesthetic Pharmaceutical Intermediates Citanest Dermal Anesthesia CAS 721-50-6

Certification
China Hengyang Desen Biotechnology Co., Ltd. certification
China Hengyang Desen Biotechnology Co., Ltd. certification
Customer Reviews
Awesome, thanks Irina. You've actually been the fastest and most responsive so far, you're going to be getting a lottt of business from me in future.

—— Andressa Hernandez from Brazil

EllenCaisin! I test the product, it is so good! Very happy. and I gave the treats to my family, you might be the best I ever used. best service!!!

—— Gabriel Collin from Canada

Aaron Fantastic! I have received the package. Thank you very much for great packaging. If it is good quality, you must have me as a long time customer

—— Mitch Kelly from USA

Yep Koala! got package thankyou so much, Koala. I like to place another order now. how much is T3 and tren a

—— Joaquin Vega from Spain

I'm Online Chat Now

Prilocaine Local Anesthetic Pharmaceutical Intermediates Citanest Dermal Anesthesia CAS 721-50-6

large.img.alt
small.img.alt small.img.alt small.img.alt small.img.alt

Large Image :  Prilocaine Local Anesthetic Pharmaceutical Intermediates Citanest Dermal Anesthesia CAS 721-50-6

Product Details:
Place of Origin: China
Brand Name: ChineseHormone
Certification: GMP, ISO 9001, USP
Model Number: CAS 721-50-6
Payment & Shipping Terms:
Minimum Order Quantity: Free samples Available
Price: negotiated
Packaging Details: as your required
Delivery Time: 3-5 working days
Payment Terms: Western Union, MoneyGram, T/T, Bitcoin
Supply Ability: 500-1000 kg / month
Detailed Product Description
MW: 220.311 MF: C13H20N2O
Appearance: White Powder Metabolism: Hepatic And Renal
Protein Binding: 55% Biological Half-life: 10-150 Minutes, Longer With Impaired Hepatic Or Renal Function
High Light:

raw pharmaceutical materials

,

raw materials for pharmaceutical products

 

Prilocaine Local Anesthetic Citanest Dermal Anesthesia Raw Powder CAS 721-50-6

 

Prilocaine (/ˈpraɪləˌkeɪn/) is a local anesthetic of the amino amide type first prepared by Claes Tegnerand Nils Löfgren. In its injectable form (trade name Citanest), it is often used in dentistry.

 

It is also often combined with lidocaine as a topical preparation for dermal anesthesia (lidocaine/prilocaine orEMLA), for treatment of conditions like paresthesia. As it has low cardiac toxicity, it is commonly used for intravenous regional anaesthesia (IVRA).

 

Contraindications

 

In some patients, ortho-toluidine, a metabolite of prilocaine, may cause methemoglobinemia, which may be treated with methylene blue. Prilocaine may also be contraindicated in people with sickle cell anemia,anemia, or symptomatic hypoxia.

 

People with pseudocholinesterase deficiency may have difficulty metabolizing this anesthetic.

 

Prilocaine Local Anesthetic Pharmaceutical Intermediates Citanest Dermal Anesthesia CAS 721-50-6 0

 

prilocaine; Citanest relatively short- to moderate-acting local anaesthetic agent of low systemic toxicity, similar tobut less vasodilatory than lidocaine; maximum safe dose = 400mg for a 70-kg adult; should not be used onpregnant/lactating women as its metabolites can cause fetal/infant methaemoglobinaemia; avoid use on patients withsevere/untreated hypertension or severe heart disease; dosage should be reduced for elderly or debilitated patients, or thosewith hepatic or renal impairment; high strengths may cause ocular toxicity (see local anaesthetic (LA) administration,pregnancy; Table 1 and Table 2)

 

Table 1: Maximum safe doses of plain local anaesthetic agents (for 70Kg adult in 24 hours)

 

Table 1: Maximum safe doses of plain local anaesthetic agents (for 70Kg adult in 24 hours)

 

Agent (brand name)

Maximum safe dose (70-kg adult) Dose per kg of body mass
Lidocaine (Xylocaine) 200mg 3mg/kg
Bupivacaine (Marcain) 150mg 2mg/kg
Levo-bupivacaine (Chirocaine) 150mg 2mg/kg
Mepivacaine (Scandonest) 400mg 6mg/kg
Prilocaine (Citanest) 400mg 6mg/kg
Ropivacaine (Naropin) 250mg 3.5mg/kg

 

Table 2: Calculation of the combined maximum safe doses (MSDs) of plain local anaesthetic agents

 

 

Table 2: Calculation of the combined maximum safe doses (MSDs) of plain local anaesthetic agents

 

Mass of drugadministered Amount of drugs administered in relation toproportional MSDs Percentage ofcombined MSD
e.g. 70-kg adult
Agent 1
6mL lidocaine2%
120mg Equivalent to (120/200) × 100% = 60% of MSDlidocaine 77%
Agent 2
5mL bupivacaine0.5%
25mg Equivalent to (25/150) × 100% = 17% of MSDbupivacaine  
e.g. 40-kg child
Agent 1
4mL lidocaine2%
80mg Equivalent to (80/120) × 100% = 77% of MSDlidocaine 89.5%
Agent 2
2mL bupivacaine0.5%
10mg Equivalent to (10/80) × 100% = 12.5% of MSDbupivacaine  

Where more than one anaesthetic agent is injected in order to achieve both rapid anaesthesia and prolonged postoperativepain relief, the proportional MSD of each of the anaesthetic agents should be calculated, in order not to exceed thecombined MSD.

 

The calculation is the product of the patient's body mass, the percentage mass of the individual anaesthetic agent and thetotal volume used of each local anaesthetic drug.

 

In the examples cited in this table, safe doses of anaesthesia would have been administered, as the combined doses ofeach anaesthetic does not exceed 100%.

 

Contact Details
Hengyang Desen Biotechnology Co., Ltd.

Contact Person: Sales Manager

Send your inquiry directly to us (0 / 3000)